

NC MEDICAID DIVISION OF HEALTH BENEFITS PREFERRED DRUG LIST REVIEW PANEL MEETING

AGENDA

Tuesday, July 22, 2025 1:00 p.m. – 5:00 p.m. Virtual Online Meeting

- I. Welcome
- II. Introductions / Medicaid Updates
- III. Overview of Panel Activities and Procedures
- IV. Drug Class Reviews, Review of Public Comments and Public Testimony

As a reminder, the PDL Panel meets once per quarter to make proposed changes. Additionally, every PDL category is reviewed at least once per calendar year. Public comments during the 30-day public comment period are allowed for categories that the State designates on the publicly posted document (any category with proposed additions and/or removals). Speakers at the PDL Panel meeting are only allowed for categories listed on the agenda for that meeting. The categories below contain recommendations that will require a vote by the PDL Panel. Those categories that are highlighted have no State recommendations but are open for discussion:

ALZHEIMER'S Agents

1. Alzheimer's Agens

Analgesics

- 1. Opioid Analgesics-Long-Acting Opioid Analgesics
- 2. Opioid Analgesics- Orally Disintegrating / Oral Spray Schedule II Opioids
- 3. Opioid Analgesics- Short Acting Schedule II Opioids
- 4. Opioid Analgesics- Short Acting Schedule III IV Opioids / Analgesic Combinations
- 5. Non-Opioid Analgesics
- 6. NSAIDS

Anticonvulsants

1. Second Generation

Anti-infectives Systemic

- 2. Antibiotics- Penicillin, Cephalosporins and Related
- 3. Antibiotics- Nitroimidazoles (Gastrointestinal Antibiotics)
- 4. Antifungals
- 5. Antivirals- General
- 6. Antivirals- Herpes Treatment

BEHAVIORAL HEALTH

- 1. Antidepressants-other
- 2. Antihyperkinesis/ADHD
- 3. Atypical Antipsychotics Oral, Transdermal

CARDIOVASCULAR

- 1. Ace Inhibitors/ Diuretic Combinations
- 2. Angiotensin II Receptor Blockers
- 3. Angiotensin II Receptor Blockers Combinations
- 4. Angiotensin II Receptor Blockers Diuretic Combinations
- 5. Angiotensin II Receptor/ Neprilysin Blocker Combinations
- 6. Beta Blockers
- 7. Beta Blockers Diuretic Combinations
- 8. Bile Acid Sequestrants
- 9. Dihydropyridine Calcium Channel Blockers

10. Oral Pulmonary Hypertension

- 11. Antianginal and Anti-Ischemic
- 12. Triglyceride Lowering Agents

CENTRAL NERVOUS SYSTEM

- 1. Antimigraine Agents- CGRP Blocker/Modulators Preventative
- 2. Antimigraine Agents- CGRP Blocker/Modulators Acute Treatment
- 7. Anti-Narcolepsy
- 8. Anitparksinson and Restless Leg syndrome Agents
- 9. Multiple Sclerosis- Injectable
- 10. Sedative Hypnotics

ENDOCRINOLOGY

- 1. Hypoglycemics- Injectables- Rapid Acting Insulin
- 2. Hypoglycemics- Injectables- Long Acting Insulin
- 3. Premixed Rapid Combination Insulin
- 4. Biguanides and Combinations

GASTROINTESTINAL

- 1. Antiemetic-Antivertigo Agents
- 2. Bile Acid Salts
- 3. H. Pylori Combinations
- 4. Pancreatic Enzymes
- 5. Proton Pump Inhibitors
- 6. Selective Constipation Agents

Ulcerative Colitis

- 1. Ulcerative Colitis- Oral Agents
- 2. Ulcerative Colitis- Rectal Agents

Genitourinary / Renal

- 1. Electrolyte Depleters- Kidney Disease
- 2. Benign Prostatic Hyperplasia Treatments
- 3. Urinary Antispasmodics

HEMATOLOGICS

- 1. Anticoagulants- Injectable
- 2. Anticoagulants- Oral
- 3. Colony Stimulating Factors
- 4. Hematopoietic Agents

OPTHALMIC

- 1. Allergic Conjunctivitis Agents
- 2. Antibiotics-Steroid Combinations
- 3. Anti-Inflammatory
- 4. Anti-Inflammatory / Immunomodulator

Osteoporosis

1. Bone Resorption Suppression and Related Agents

OTIC

1. Anti-Inflammatory

RESPIRATORY

- 1. Beta-Adrenergic Handheld, Short-Acting
- 2. Inhaled Corticosteroids
- 3. Inhaled Corticosteroid Combinations
- 4. Intranasal Rhinitis Agents

TOPICALS

- 1. Acne Agents
- 2. Antibiotics- Vaginal
- 3. Antifungals
- 4. Antiviral
- 5. Psoriasis
- 6. Rosacea Agents
- 7. Steroids- High Potency
- 8. Steroids- Very High Potency

MISCELLANEOUS

- 1. Uterine Disorder Treatments
- 2. Immunomodulators- Atopic Dermatitis
- 3. Epinephrine- Self Administered
- 4. Estrogen Agents, Vaginal Preparations
- 5. Glucocorticoid Steroid- Oral
- 6. Cytokine and Cam Antagonists
- 7. Immunosuppressants
- 8. Movement Disorders
- 9. Hereditary Angioedema (HAE) Treatment Agents

DIABETIC CONTINIOUS GLUCOSE MONITOR SUPPLIES

- 1. Continuous Glucose Monitor Transmitters / Receivers / Readers
- V. Closing comments and adjournment